Nektar Therapeutics Soars 156.5% on Positive Atopic Dermatitis Study Results

Nektar Therapeutics' stock surged 156.5% in pre-market trading on June 24, 2025, driven by significant positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in treating atopic dermatitis.

Nektar Therapeutics announced that its Phase 2b REZOLVE-AD study of rezpegaldesleukin met all key endpoints, demonstrating the drug's efficacy in treating moderate-to-severe atopic dermatitis. This study is part of the company's broader immunology pipeline, which includes three separate Phase 2 studies focusing on ResPEGaldu leukin.

The company is also evaluating rezpegaldesleukin in alopecia areata, with Phase 2b data expected in the fourth quarter of 2025. Nektar Therapeutics plans to continue monitoring patients in these studies to gather more comprehensive data on the drug's long-term effects and efficacy.

Nektar Therapeutics is in a strong financial position, with a cash runway extending into the fourth quarter of 2026. The company is progressing with IND-enabling studies for its TNFR2 agonist antibody program, Nectar 165, and expects to submit an IND filing in 2025. Additionally, Nektar Therapeutics has a collaboration with the Fred Hutchinson Cancer Center, with data from their study being presented at the European Hematology Association congress.